May 16, 2023
Via: World Pharma NewsBayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news […]
July 11, 2024
July 11, 2024
July 19, 2024